Mid to long-term clinical outcomes improvement through dual antiplatelet therapy after coronary artery bypass grafting:Interpretation of DACAB-FE trial
Coronary artery bypass grafting(CABG)is one of the most effective revascularization treatments for coronary heart disease.Secondary prevention strategies,which rely on antiplatelet and lipid-lowering drugs,are crucial after CABG to ensure the durability of revascularization treatment effects and prevent adverse cardiovascular and cerebrovascular events in the medium to long term.Previous research conducted by Professor Zhao Qiang's team from Ruijin Hospital of Shanghai Jiao Tong University,known as the DACAB study,indicated that dual antiplatelet therapy(DAPT,specifically ticagrelor+aspirin)after CABG can enhance venous graft patency.However,it remains uncertain whether DAPT can further improve the medium to long-term clinical outcomes of CABG patients.Recently,the team reported the medium to long-term follow-up results of the DACAB study,termed the DACAB-FE study,finding that DAPT administered after CABG can reduce the incidence of major cardiovascular events over five years and improve patients'medium to long-term clinical outcomes.This article will interpret the methodological highlights and significant clinical implications of the DACAB-FE study.
Dual antiplatelet therapycoronary artery bypass graftingmedium to long-term clinical outcome
NETL
NSTL
万方数据
